Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.6373 |
| Volume | 28 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by a senior executive following the re-investment of dividends paid on July 14, 2016, under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of an insider transaction.
Key Facts for Investor Verification
- Executive Identity: The transaction involves Mr. P C Thomson, SVP of Communications & Government Affairs.
- Transaction Nature: The purchase was an automatic re-investment of dividends, not a discretionary open-market purchase.
- Volume Significance: The volume of 28 shares is nominal and does not indicate a significant change in executive ownership.
- Financial Data Absence: Investors should refer to the company's Form 20-F or interim results for actual financial performance metrics.